Clinical Trial Update: Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating short-course tislelizumab in combination with chemoradiotherapy for nasopharyngeal carcinoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer | Phase 3 | Status: NOT_YET_RECRUITING